Trial Profile
Post-hoc analysis assessing changes with sarilumab in Rheumatoid arthritis patient reported outcomes (PROs) among patients with 1° or 2° TNFi failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARGET
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results of Post-hoc analysis, presented at the 19th Annual Congress of the European League Against Rheumatism